Ilya Zubarev

Dr. Ilya Zubarev

Laboratory of Cell Signaling Regulation, Moscow Institute of Physics and Technology, Dolgoprudny, Russia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2016 in Toxicology
Verified
Journal Article
Closed access
Marina P. Petrovna SutunkovaMarina P. Petrovna Sutunkova
Marina P. Petrovna Sutunkova
BKBoris Katsnelson
Boris Katsnelson
LPL.I. Privalova
L.I. Privalova
VGV.B. Gurvich
V.B. Gurvich
LKL.K. Konysheva
L.K. Konysheva
IZIlya Zubarev
Ilya Zubarev

10 June 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
ALAnastasiia A. Latypova
Anastasiia A. Latypova
AYAlexey V. Yaremenko
Alexey V. Yaremenko
NPNadezhda A. Pechnikova
Nadezhda A. Pechnikova
AMArtem S. Minin
Artem S. Minin
IZIlya Zubarev
Ilya Zubarev
Magnetogenetics emerges as a transformative approach for modulating cellular signaling pathways through the strategic application of magnetic fields and nanoparticles. This technique leverages the unique properties of magnetic nanoparticles (MNPs) to induce mechanical or thermal stimuli within cells, facilitating the activation of mechano- and thermosensitive proteins without the need for traditional ligand-receptor interactions. Unlike traditional modalities that often require invasive interventions and lack precision in targeting specific cellular functions, magnetogenetics offers a non-invasive alternative with the capacity for deep tissue penetration and the potential for targeting a broad spectrum of cellular processes. This review underscores magnetogenetics’ broad applicability, from steering stem cell differentiation to manipulating neuronal activity and immune responses, highlighting its potential in regenerative medicine, neuroscience, and cancer therapy. Furthermore, the review explores the challenges and future directions of magnetogenetics, including the development of genetically programmed magnetic nanoparticles and the integration of magnetic field-sensitive cells for in vivo applications. Magnetogenetics stands at the forefront of cellular manipulation technologies, offering novel insights into cellular signaling and opening new avenues for therapeutic interventions.

1 June 2017 in Toxicology
Verified
Journal Article
Closed access
Marina P. Petrovna SutunkovaMarina P. Petrovna Sutunkova
Marina P. Petrovna Sutunkova
SSSvetlana N. Solovyeva
Svetlana N. Solovyeva
BKBoris Katsnelson
Boris Katsnelson
VGVladimir B. Gurvich
Vladimir B. Gurvich
LPLarisa I. Privalova
Larisa I. Privalova
ESEkaterina V. Shishkina
Ekaterina V. Shishkina

Verified
Journal Article
Open access
PDF file
Vol V. OberemokVol V. Oberemok
Vol V. Oberemok
KLKateryna Laikova
Kateryna Laikova
AZAleksei S. Zaitsev
Aleksei S. Zaitsev
MSMaksym Shumskykh
Maksym Shumskykh
IKIgor N. Kasich
Igor N. Kasich
Oleksii SkorokhodOleksii Skorokhod
Oleksii Skorokhod
Baculovirus IAP (inhibitor-of-apoptosis) genes originated by capture of host genes. Unmodified short antisense DNA oligonucleotides (oligoDNAs) from baculovirus IAP genes can down-regulate specific gene expression profiles in both baculovirus-free and baculovirus-infected insects. In this study, gypsy moth (Lymantria dispar) larvae infected with multiple nucleopolyhedrovirus (LdMNPV), and LdMNPV-free larvae, were treated with oligoDNA antisense to the RING (really interesting new gene) domain of the LdMNPV IAP-3 gene. The results with respect to insect mortality, biomass accumulation, histological studies, RT-PCR, and analysis of DNA apoptotic fragmentation suggest that oligoRING induced increased apoptotic processes in both LdMNPV-free and LdMNPV-infected insect cells, but were more pronounced in the latter. These data open up possibilities for promising new routes of insect pest control using antisense phosphodiester DNA oligonucleotides.

9 December 2024 in Advanced Functional Materials
Verified
Journal Article
Open access
NPNadezhda Pechnikova
Nadezhda Pechnikova
AAAmalia Aggeli
Amalia Aggeli
ALAnastasiia Latypova
Anastasiia Latypova
AIAleksandra V. Iaremenko
Aleksandra V. Iaremenko
Kelly DomvriKelly Domvri
Kelly Domvri
AYAlexey V. Yaremenko
Alexey V. Yaremenko
Cancer immunotherapy has revolutionized cancer treatment by leveraging the immune system to target and eliminate tumor cells. Implantable biomaterials, such as hydrogels, sponges, scaffolds, implantable microdevice platforms, and macrobeads, offer localized and sustained release of immunomodulatory agents, improving the delivery of treatments such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies like CAR‐T cells. This review examines the emerging role of these biomaterials in modulating the tumor microenvironment, enhancing immune cell recruitment, and reducing systemic side effects, positioning them as significant tools for treating solid tumors. Recent advances in material engineering are also discussed, including the integration of bioactive molecules and real‐time therapeutic adjustments based on patient‐specific immune responses, which offer new potential in personalized cancer treatments. However, challenges such as biocompatibility, high production costs, variability in patient response, and the necessity of surgical manipulations remain key obstacles. Nonetheless, ongoing research and technological advancements are steadily addressing these issues, paving the way for more effective and accessible cancer immunotherapies. Overall, this review highlights the promise of implantable biomaterials overcoming the current limitations of cancer immunotherapy and expanding the scope of effective, targeted cancer treatments.